Cited by 78Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing

Open access

Shiau, Carolyn J., Babwah, Jesse P., da Cunha Santos, Gilda, Sykes, Jenna R., Boerner, Scott L., Geddie, William R., Leighl, Natasha B., Wei, Cuihong, Kamel-Reid, Suzanne, Hwang, David M., Tsao, Ming-Sound·2014·Journal of Thoracic Oncology

DOI 10.1097/jto.0000000000000196

Open this paper in CoChat — free account Open PDF

Abstract

Introduction Epidermal growth factor receptor (EGFR) mutation testing has become critical in the treatment of patients with advanced non-small-cell lung cancer. This study involves a large cohort and epidemiologically unselected series of EGFR mutation testing for patients with nonsquamous non-small-cell lung cancer in a North American population to determine sample-related factors that influence success in clinical EGFR testing.Methods Data from consecutive cases of Canadian province-wide testing at a centralized diagnostic laboratory for a 24-month period were reviewed. Samples were tested for exon-19 deletion and exon-21 L858R mutations using a validated polymerase chain reaction method with 1% to 5% detection sensitivity.Results From 2651 samples submitted, 2404 samples were tested with 2293 samples eligible for analysis (1780 histology and 513 cytology specimens). The overall test-failure rate was 5.4% with overall mutation rate of 20.6%. No significant differences in the failure rate, mutation rate, or mutation type were found between histology and cytology samples. Although tumor cellularity was significantly associated with test-success or mutation rates in histology and cytology specimens, respectively, mutations could be detected in all specimen types. Significant rates of EGFR mutation were detected in cases with thyroid transcription factor (TTF)-1-negative immunohistochemistry (6.7%) and mucinous component (9.0%).Conclusions EGFR mutation testing should be attempted in any specimen, whether histologic or cytologic. Samples should not be excluded from testing based on TTF-1 status or histologic features. Pathologists should report the amount of available tumor for testing. However, suboptimal samples with a negative EGFR mutation result should be considered for repeat testing with an alternate sample.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/jto.0000000000000196

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Multiple imputation using chained equations: Issues and guidance for practice
White, I. R., Royston, P., & Wood, A. M. (2011) · Statistics in Medicine · doi:10.1002/sim.4067 · Cited by 9,792
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
Travis, W. D., Brambilla, E. M., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Schil, P. E. V., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,834
Self-citation
Multiple imputation: a primer
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
New driver mutations in non-small-cell lung cancer
Pao, W. J., & Girard, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70087-5 · Cited by 1,200
EGFR Mutations and Lung Cancer
Santos, G. D. C., Shepherd, F. A., & Tsao, M. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130206 · Cited by 964
Self-citation
New driver mutations in non-small-cell lung cancer
Tanoue, L. T. (2012) · Yearbook of Pulmonary Disease · doi:10.1016/j.ypdi.2012.01.036 · Cited by 833
Non–Small Cell Lung Cancer
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 737
Non–Small Cell Lung Cancer
Ettinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A. C., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., Ganti, A. K., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0056 · Cited by 729
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
Shigematsu, H., & Gazdar, A. F. (2005) · International Journal of Cancer · doi:10.1002/ijc.21496 · Cited by 668
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
Zhu, C.-Q., da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J.-C., Liu, N., Zhang, T., Marrano, P., Whitehead, M., Squire, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8924 · Cited by 661
Self-citation
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.001 · Cited by 461
Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung Cancer
Amann, J. M., Kalyankrishna, S., Massion, P. P., Ohm, J. E., Girard, L., Shigematsu, H., Peyton, M., Juroske, D. M., Huang, Y., Salmon, J. S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.226.65.1 · Cited by 432
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Đačić, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J., Squire, J. A., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0720-oa · Cited by 426
Initial Diagnosis of Lung Cancer
Rivera, M. P., & Mehta, A. C. (2007) · CHEST Journal · doi:10.1378/chest.07-1357 · Cited by 422
Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer
Riely, G. J., Politi, K. A., Miller, V. A., & Pao, W. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0658 · Cited by 363
Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer
Doebele, R. C., Lu, X. J. D., Sumey, C. J., Maxson, D. A., Weickhardt, A. J., Oton, A. B., Bunn, P. A., Barón, A. E., Franklin, W. A., Aisner, D. L., et al. (2012) · Cancer · doi:10.1002/cncr.27409 · Cited by 280
Molecular pathology of lung cancer: key to personalized medicine
Liang Cheng, C., Alexander, R. E., MacLennan, G. T., Cummings, O. W., Montironi, R., Antonio Lopez-beltran, B., Cramer, H. M., Davidson, D. D., & Zhang, S. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.215 · Cited by 249
Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas
Pan, Q., Pao, W. J., & Ladanyi, M. (2005) · Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60569-7 · Cited by 245
EGFR and KRAS mutations in lung carcinoma
Billah, S., Stewart, J., Staerkel, G., Chen, S., Gong, Y., & Guo, M. (2011) · Cancer Cytopathology · doi:10.1002/cncy.20151 · Cited by 226
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
Jänne, P. A., Borras, A. M., Kuang, Y., Rogers, A. M., Joshi, V. A., Liyanage, H., Lindeman, N., Lee, J. C., Halmos, B., Maher, E. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2047 · Cited by 214
The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies
Liu, X., Lu, Y., Zhu, G., Yao, L., Li, Z., Qin, H., Tang, C., Ellison, G., McCormack, R., & Ji, Q. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201728 · Cited by 146
A Novel Classification of Lung Cancer into Molecular Subtypes
West, L. E., Vidwans, S. J., Campbell, N. P., Shrager, J., Simon, G. R., Bueno, R., Dennis, P. A., Otterson, G. A., & Salgia, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031906 · Cited by 125
High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non‐small cell lung cancer patients
Kimura, H., Fujiwara, Y., Sone, T., Kunitoh, H., Tamura, T., Kasahara, K., & Nishio, K. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00216.x · Cited by 125
EGFR Mutation Status in Primary Lung Adenocarcinomas and Corresponding Metastatic Lesions: Discordance in Pleural Metastases
Han, H., Eom, D., Kim, J. H., Kim, K., Shin, H.-M., An, J. Y., Lee, K. M., Choe, K. H., Lee, K. H., Kim, S. T., et al. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.02.006 · Cited by 119
EGFR gene status in cytological samples of nonsmall cell lung carcinoma
Santos, G. D. C., Saieg, M. A., Geddie, W. R., & Leighl, N. B. (2011) · Cancer Cytopathology · doi:10.1002/cncy.20150 · Cited by 116
Self-citation
Clinical and molecular analysis of synchronous double lung cancers
Arai, J., Tsuchiya, T., Oikawa, M., Mochinaga, K., Hayashi, T., Yoshiura, K.-I., Tsukamoto, K., Yamasaki, N., Matsumoto, K., Miyazaki, T., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.04.003 · Cited by 112
Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic features
Sekine, A., Kato, T., Hagiwara, E., Shinohara, T., Komagata, T., Iwasawa, T., Satoh, H., Tamura, K., Kasamatsu, T., Hayashihara, K., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.017 · Cited by 97
A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer
Ellis, P. M., Blais, N., Soulieres, D., Ionescu, D. N., Kashyap, M., Liu, G., Melosky, B., Reiman, T., Romeo, P., Shepherd, F. A., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318220cb8e · Cited by 96
Self-citation
EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection
Roy‐Chowdhuri, S., Xi, L., Pham, T. H.-T., Hanson, J. C., Rodriguez‐Canales, J., Berman, A. W., Rajan, A., Giaccone, G., Emmert‐Buck, M. R., Raffeld, M. A., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.184 · Cited by 74
Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies
Warth, A., Penzel, R., Brandt, R., Sers, C., Fischer, J. R., Thomas, M., Herth, F. J. F., Dietel, M., Schirmacher, P., & Bläker, H. (2012) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-012-1219-x · Cited by 71
Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma
Togashi, Y., Masago, K., Kubo, T., Sakamori, Y., Kim, Y. H., Hatachi, Y., Fukuhara, A., Mio, T., Togashi, K., & Mishima, M. (2010) · Cancer · doi:10.1002/cncr.25618 · Cited by 64
EGFR and KRAS mutations in metastatic lung adenocarcinomas
Munfus-McCray, D., Harada, S., Adams, C., Askin, F. B., Clark, D. P., Gabrielson, E., & Li, Q. K. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.12.011 · Cited by 57
Personalized Medicine for Non–Small-Cell Lung Cancer: Implications of Recent Advances in Tissue Acquisition for Molecular and Histologic Testing
Moreira, A. L., & Thornton, R. H. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.01.004 · Cited by 52
FrequentEGFRmutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis
Wu, S., Hu, F., Chang, Y., Lee, Y.-C., Yu, C., Chang, Y., Wu, J., Shih, J., & Yang, P. (2012) · European Respiratory Journal · doi:10.1183/09031936.00006912 · Cited by 49
The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory's analysis of 670 cases
Pang, B., Matthias, D., Ong, C. W., Dhewar, A. N., Gupta, S., Lim, G. L., Nga, M. E., Seet, J. E., Qasim, A., Chin, T. M., et al. (2012) · Cytopathology · doi:10.1111/j.1365-2303.2012.01000.x · Cited by 47
Clinical Significance of Thyroid Transcription Factor-1 in Advanced Lung Adenocarcinoma Under Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment
Chung, K., Huang, Y., Chang, Y., Yu, C., Yang, C.-H., Chang, Y., Shih, J., & Yang, P. (2011) · CHEST Journal · doi:10.1378/chest.10-3149 · Cited by 47
Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non–Small-Cell Lung Cancer in a Publicly Funded Health Care System
Ellis, P. M., Verma, S., Sehdev, S. R., Younus, J., & Leighl, N. B. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f6a43 · Cited by 46
Self-citation
Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non‐small cell lung cancer
Hagiwara, K., & Kobayashi, K. (2012) · Cancer Science · doi:10.1111/cas.12081 · Cited by 42
Establishing an EGFR mutation screening service for non-small cell lung cancer – Sample quality criteria and candidate histological predictors
Leary, A. F., de Castro, D. G., Nicholson, A. G., Ashley, S. E., Wotherspoon, A. C., O'Brien, M. E. R., & Popat, S. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.022 · Cited by 40
Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach
Salto‐Tellez, M., Tsao, M., Shih, J., Thongprasert, S., Lü, S., Chang, G., Au, J. S. K., Chou, T., Lee, J. S., Shi, Y.-K., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318227816a · Cited by 38
Self-citation
Negative NKX2-1 (TTF-1) as Temporary Surrogate Marker for Treatment Selection During EGFR-Mutation Analysis in Patients with Non–Small-Cell Lung Cancer
Vincenten, J. P. L., Smit, E. F., Vos, W., Grünberg, K., Postmus, P. E., Heideman, D. A. M., Snijders, P. J. F., Meijer, G. A., Kuik, J. D., Lissenberg-Witte, B. I., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182635a91 · Cited by 28
EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer
Kamel‐Reid, S., Chong, G., Ionescu, D. N., Magliocco, A. M., Spatz, A., Tsao, M., Weng, X., Young, S. S., Zhang, T., & Soulières, D. (2012) · Current Oncology · doi:10.3747/co.19.862 · Cited by 18
Self-citation
Evaluation of 2-Year Experience With EGFR Mutation Analysis of Small Diagnostic Samples
Hlinkova, K., Babál, P., Berzinec, P., Majer, I., Mikle-Barathova, Z., Piackova, B., & Ilenčíková, D. (2013) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31827e6984 · Cited by 17
Molecular Diagnostics of Lung Cancers at the Brigham and Women's Hospital and Dana-Farber Cancer Institute: Technology in Rapid Evolution
Lindeman, N. I. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0277-ra · Cited by 8

Sorted by citations

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M., Beasley, M. B., Borczuk, A., Brambilla, E. M., Cooper, W. A., Đačić, S., Jain, D., Kerr, K. M., Lantuéjoul, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,656
Self-citation
Integrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3520 · Cited by 1,100
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
Stewart, E., Tan, S. Z., Liu, G., & Tsao, M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.11.06 · Cited by 314
Self-citation
Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy
Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 250
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201
Self-citation

See all 78

Authors: Shiau, C. J., Babwah, J. P., da Cunha Santos, G., Sykes, J. R., Boerner, S. L., Geddie, W. R., Leighl, N. B., Wei, C., Kamel-Reid, S., Hwang, D. M., & Tsao, M.-S.
Affiliations: University Health Network (CA)
University of Toronto (CA)
Corresponding author: Tsao, Ming-Sound
ORCID: Shiau, Carolyn J.
Sykes, Jenna R.
Boerner, Scott L.
Leighl, Natasha B.
Hwang, David M.
Tsao, Ming-Sound
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2014-07
Volume: 9
Issue: 7
Pages: 947-956
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1097/jto.0000000000000196
OpenAlex: W2003360283
Cited by: 78
References: 46
Citations by year: 2026: 1 · 2025: 4 · 2024: 2 · 2023: 6 · 2022: 10 · 2021: 7 · 2020: 5 · 2019: 5 · 2018: 10 · 2017: 12 · 2016: 8 · 2015: 5 · 2014: 2
FWCI: 7.21
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 519 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca Canada
Ontario Ministry of Health and Long-Term Care
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: EGFR mutation testing, non-small cell lung cancer, test failure rate, tumor cellularity, cytology specimens, exon 19 deletion, L858R mutation, retesting
MeSH terms: Thyroid Nuclear Factor 1, Base Sequence, Biopsy, Needle, Canada, Carcinoma, Non-Small-Cell Lung, Cytological Techniques, DNA Mutational Analysis, Exons, Female, Genetic Testing, Humans, Lung Neoplasms, Male, Nuclear Proteins, Pneumonectomy, Retrospective Studies, Transcription Factors, Sequence Deletion, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks